Buy Rating for Liquidia Technologies: Anticipated FDA Approval and Market Expansion Drive Positive Outlook

Serge Belanger, an analyst from Needham, maintained the Buy rating on Liquidia Technologies (LQDA – Research Report). The associated price target was raised to $25.00.

Serge Belanger has given his Buy rating due to a combination of factors that highlight Liquidia Technologies’ promising future. One of the key reasons is the anticipated FDA approval and subsequent U.S. launch of Yutrepia, which is expected to occur once the regulatory exclusivity on Tyvaso DPI expires in mid-2025. This launch positions Liquidia to tap into a growing market for PAH and PH-ILD treatments, which is projected to expand significantly in the coming years.
Belanger also notes that Yutrepia is poised to be a strong competitor in this market due to its differentiated features compared to Tyvaso DPI. These include a more advanced inhaler device and improved tolerability, which could allow for higher dosing levels and potentially better patient outcomes. In light of these factors, Belanger has increased the price target for Liquidia’s stock, reflecting expectations of higher sales for Yutrepia and a positive outlook for the company’s financial performance.